FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1500789283> ?p ?o ?g. }

• W1500789283 endingPage "485" @default.
• W1500789283 startingPage "482" @default.
• W1500789283 abstract "Seminars in DialysisVolume 23, Issue 5 p. 482-485 Clinical Relevance of Impaired Nonrenal Drug Clearance in ESRD Thomas D. Nolin, Thomas D. Nolin Department of Pharmacy and Therapeutics, and Center for Clinical Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, Pennsylvania Renal-Electrolyte Division, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaSearch for more papers by this authorMark L. Unruh, Mark L. Unruh Renal-Electrolyte Division, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaSearch for more papers by this author Thomas D. Nolin, Thomas D. Nolin Department of Pharmacy and Therapeutics, and Center for Clinical Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, Pennsylvania Renal-Electrolyte Division, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaSearch for more papers by this authorMark L. Unruh, Mark L. Unruh Renal-Electrolyte Division, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaSearch for more papers by this author First published: 29 October 2010 https://doi.org/10.1111/j.1525-139X.2010.00775.xCitations: 10 Address correspondence to: Thomas D. Nolin, PharmD, PhD, University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, 808 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261 USA, Tel.: +1-412-624-4683, Fax: +1-412-624-1850, or e-mail: [email protected]. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Dettli L: Drug dosage in renal disease. Clin Pharmacokinet 1: 126– 134, 1976 2 Bennett WM: Guide to drug dosage in renal failure. Clin Pharmacokinet 15: 326– 354, 1988 3 Nolin TD, Naud J, Leblond FA, Pichette V: Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83: 898– 903, 2008 4 Dreisbach AW: The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 86: 553– 556, 2009 5 Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, Petersen LA, Small SD, Sweitzer BJ, Vander VM, Leape LL: Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 159: 2553– 2560, 1999 6 Manley HJ, Cannella CA, Bailie GR, St Peter WL: Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 46: 669– 680, 2005 7 Joshua L, Devi PD, Guido S: Adverse drug reactions in nephrology ward inpatients of a tertiary care hospital. Indian J Med Sci 61: 562– 569, 2007 8 Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, Holla V, Helvig C: Human cytochromes P450. Mol Aspects Med 20: 1– 137, 1999 9 Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21: 70– 83, 2008 10 Testa B, Kramer SD: The biochemistry of drug metabolism--an introduction: part 4. reactions of conjugation and their enzymes. Chem Biodivers 5: 2171– 2336, 2008 11 Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L: Membrane transporters in drug development. Nat Rev Drug Discov 9: 215– 236, 2010 12 Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58: 521– 590, 2006 13 Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83– 448, 2002 14 Rendic S, Guengerich FP: Update information on drug metabolism systems–2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 11: 4– 84, 2010 15 Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78: 260– 277, 2005 16 Leblond FA, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326– 332, 2001 17 Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V: Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 13: 1579– 1585, 2002 18 Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A, Guillemette C, Sim E, Pichette V: Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 19: 1352– 1359, 2008 19 Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, Pichette V: Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320: 978– 985, 2007 20 Naud J, Michaud J, Lebond FA, Lefrancois S, Bonnardeaux A, Pichette V: Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 36: 124– 128, 2008 21 Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J: ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 20: 2269– 2276, 2009 22 Sun H, Frassetto LA, Huang Y, Benet LZ: Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 87: 465– 472, 2010 23 Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, Xiao S, Atkinson AJ, Jr, Thummel KE, Leeder JS, Lee C, Burckart GJ, Lesko LJ, Huang SM: Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 85: 305– 311, 2009 24 Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ: When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther 86: 475– 479, 2009 25 Product Information: Cialis (tadalafil). Indianapolis, IN: Eli Lilly and Co., 2010 26 Marbury TC, Ruckle JL, Hatorp V, et al.: Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67: 7– 15, 2000. 27 Product Information: Prandin (repaglinide). Princeton, NJ: Novo Nordisk Inc., 2010 28 Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59: 602– 604, 2005 29 Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77: 468– 478, 2005 30 Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63: 115– 120, 2009 31 Romaine SP, Bailey KM, Hall AS, Balmforth AJ: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10: 1– 11, 2010 32 Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81: 362– 370, 2007 33 Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53: 526– 534, 2002 34 Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80: 356– 366, 2006 35 Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82: 726– 733, 2007 36 Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873– 879, 2006 37 Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609– 1616, 2009 38 Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 359: 789– 799, 2008 Citing Literature Volume23, Issue5September/October 2010Pages 482-485 ReferencesRelatedInformation" @default.
• W1500789283 created "2016-06-24" @default.
• W1500789283 creator A5040217042 @default.
• W1500789283 creator A5043993000 @default.
• W1500789283 date "2010-09-01" @default.
• W1500789283 modified "2023-10-12" @default.
• W1500789283 title "Clinical Relevance of Impaired Nonrenal Drug Clearance in ESRD" @default.
• W1500789283 cites W1604547439 @default.
• W1500789283 cites W1969592782 @default.
• W1500789283 cites W1992237854 @default.
• W1500789283 cites W1993776708 @default.
• W1500789283 cites W2002047267 @default.
• W1500789283 cites W2010396854 @default.
• W1500789283 cites W2018217049 @default.
• W1500789283 cites W2019150978 @default.
• W1500789283 cites W2025294597 @default.
• W1500789283 cites W2026977556 @default.
• W1500789283 cites W2050094658 @default.
• W1500789283 cites W2056508624 @default.
• W1500789283 cites W2063610505 @default.
• W1500789283 cites W2076194172 @default.
• W1500789283 cites W2079197876 @default.
• W1500789283 cites W2079296200 @default.
• W1500789283 cites W2088270471 @default.
• W1500789283 cites W2089526947 @default.
• W1500789283 cites W2092566765 @default.
• W1500789283 cites W2097100227 @default.
• W1500789283 cites W2108825946 @default.
• W1500789283 cites W2113524447 @default.
• W1500789283 cites W2121055261 @default.
• W1500789283 cites W2129209019 @default.
• W1500789283 cites W2134954841 @default.
• W1500789283 cites W2139681313 @default.
• W1500789283 cites W2140759033 @default.
• W1500789283 cites W2141768943 @default.
• W1500789283 cites W2146348626 @default.
• W1500789283 cites W2152218609 @default.
• W1500789283 cites W2153372327 @default.
• W1500789283 cites W2153709558 @default.
• W1500789283 cites W2155634239 @default.
• W1500789283 cites W2171279314 @default.
• W1500789283 cites W2951360964 @default.
• W1500789283 cites W4249964811 @default.
• W1500789283 doi "https://doi.org/10.1111/j.1525-139x.2010.00775.x" @default.
• W1500789283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21069923" @default.
• W1500789283 hasPublicationYear "2010" @default.
• W1500789283 type Work @default.
• W1500789283 sameAs 1500789283 @default.
• W1500789283 citedByCount "12" @default.
• W1500789283 countsByYear W15007892832012 @default.
• W1500789283 countsByYear W15007892832014 @default.
• W1500789283 countsByYear W15007892832015 @default.
• W1500789283 countsByYear W15007892832016 @default.
• W1500789283 countsByYear W15007892832017 @default.
• W1500789283 countsByYear W15007892832018 @default.
• W1500789283 crossrefType "journal-article" @default.
• W1500789283 hasAuthorship W1500789283A5040217042 @default.
• W1500789283 hasAuthorship W1500789283A5043993000 @default.
• W1500789283 hasConcept C126322002 @default.
• W1500789283 hasConcept C158154518 @default.
• W1500789283 hasConcept C17744445 @default.
• W1500789283 hasConcept C177713679 @default.
• W1500789283 hasConcept C199539241 @default.
• W1500789283 hasConcept C2780035454 @default.
• W1500789283 hasConcept C63363279 @default.
• W1500789283 hasConcept C71924100 @default.
• W1500789283 hasConcept C98274493 @default.
• W1500789283 hasConceptScore W1500789283C126322002 @default.
• W1500789283 hasConceptScore W1500789283C158154518 @default.
• W1500789283 hasConceptScore W1500789283C17744445 @default.
• W1500789283 hasConceptScore W1500789283C177713679 @default.
• W1500789283 hasConceptScore W1500789283C199539241 @default.
• W1500789283 hasConceptScore W1500789283C2780035454 @default.
• W1500789283 hasConceptScore W1500789283C63363279 @default.
• W1500789283 hasConceptScore W1500789283C71924100 @default.
• W1500789283 hasConceptScore W1500789283C98274493 @default.
• W1500789283 hasIssue "5" @default.
• W1500789283 hasLocation W15007892831 @default.
• W1500789283 hasLocation W15007892832 @default.
• W1500789283 hasOpenAccess W1500789283 @default.
• W1500789283 hasPrimaryLocation W15007892831 @default.
• W1500789283 hasRelatedWork W1983544050 @default.
• W1500789283 hasRelatedWork W2124466768 @default.
• W1500789283 hasRelatedWork W2125138090 @default.
• W1500789283 hasRelatedWork W2141845144 @default.
• W1500789283 hasRelatedWork W2160274156 @default.
• W1500789283 hasRelatedWork W2564299030 @default.
• W1500789283 hasRelatedWork W2794783788 @default.
• W1500789283 hasRelatedWork W2997518748 @default.
• W1500789283 hasRelatedWork W3024440267 @default.
• W1500789283 hasRelatedWork W4213271907 @default.
• W1500789283 hasVolume "23" @default.
• W1500789283 isParatext "false" @default.
• W1500789283 isRetracted "false" @default.
• W1500789283 magId "1500789283" @default.
• W1500789283 workType "article" @default.